| Health risks:
|Important safety remarks:
25I-NBOH (NBOH-2CI, Cimbi-27) is a derivative of the phenethylamine derived hallucinogen 2C-I. It acts as a potent agonist for the 5HT2A receptor, with a Ki of 0.061nM at the human 5HT2A receptor, making it some twelve times the potency of 2C-I itself. In contrast to 25I-NBOMe with a Ki of 0.044 nM (sixteen times the potency of 2C-I). Therefore treat 25I-NBOH like you would treat 25I-NBOMe.
It was discovered in 2006 by a team at Purdue University.
- Activity via sublingual administration or parenteral starts at well below one milligram (full activity at 500-700µg) and may be fatal in high doses!
- Doses lower than one milligram have reported some visual and cognitive activity, though reports are not detailed/well-defined.
- bluelight.org: The Big Dandy 25I-NBOH Thread
- drugs-forum.com: 25I-NBOH Experiences
- isomerdesign.com: 25I-NBOH
- wikipedia.org: 25I-NBOH
- eve-rave.ch: 25i/c-nboh (German)